Gallbladder disease on Mounjaro (tirzepatide for T2D): Incidence, Severity, and Realistic Expectations

What the Mounjaro label reports

Mounjaro is a once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes in adults and children 10 years and older, and for reducing major cardiovascular events in adults with type 2 diabetes at high risk [1]. It is not labeled for weight loss [1].

The label's gallbladder figure is 0.6% with tirzepatide and 0% with placebo in Mounjaro placebo-controlled clinical trials in adults. The label defines the event as acute gallbladder disease and lists cholelithiasis, biliary colic and cholecystectomy within that term. It gives the figure as a single pooled number, not one for each dose or each event [1].

The label's warning says that if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated [1]. Suspected pancreatitis is a separate warning, for which the label says Mounjaro is to be discontinued [1].

What the meta-analysis adds

A 2023 systematic review and meta-analysis pooled nine randomized trials with 9,871 participants: 6,828 assigned to tirzepatide and 3,043 to control [2]. The composite of gallbladder or biliary disease was significantly more common with tirzepatide than with placebo or basal insulin (RR 1.97, 95% CI 1.14 to 3.42) [2]. The same analysis did not find a significant increase for cholelithiasis, cholecystitis or biliary diseases when each was analyzed alone [2]. The label's 0.6% and the meta-analysis's positive result are both composites.

A larger 2025 meta-analysis looked across the GLP-1 receptor agonist class: 21 trials, 99,599 patients, eight drugs including tirzepatide, mean follow-up 2.4 years [3]. It found a 26% increase in gallbladder disorders with GLP-1 receptor agonists versus controls. That is a class estimate, not a Mounjaro-specific one.

Estimates differ by population. A 2025 meta-analysis of 13 trials in 26,894 adults with obesity but without diabetes found semaglutide increased gallbladder-related disorders by more than 2.6-fold, while tirzepatide showed no significant biliary risk [4]. That review studied a different group from the type 2 diabetes trials behind the Mounjaro label [1][4].

How severe are the events?

The label's 0.6% includes biliary colic and cholecystectomy, so gallbladder removal is one of the outcomes counted in that figure, not only mild symptoms [1].

Is gallbladder disease a contraindication?

No. The label's contraindications are a personal or family history of medullary thyroid carcinoma or MEN 2, and known serious hypersensitivity to tirzepatide or an excipient. Gallbladder disease is addressed as a warning [1].